ETST · XBRL financial data

Earth Science Tech financial statements, every fiscal year

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ETST's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue from contracts with customers	141	14	49	11,954	33,118	35,696
Cost of revenue	101	23	26	—	—	—
Cost of goods and services sold	—	—	26	4,125	8,817	10,208
Gross profit	40	(9)	22	7,828	24,300	25,488
Research and development	9	0	0	—	—	—
Selling, general and administrative	—	—	232	167	4,155	3,571
General and administrative	229	116	232	—	—	—
Total operating expenses	4,342	218	959	6,936	20,852	22,180
Operating income (loss)	(4,302)	(227)	(937)	892	—	—
Interest expense	5	11	47	67	21	16
Other income (expense)	—	—	619	—	—	67
Income tax expense (benefit)	—	—	—	13	117	(512)
Net income (loss)	(4,383)	3,173	(365)	812	3,254	3,631
Earnings per share, basic USD per share	(0.08)	0.06	(0.00)	0.00	0.01	0.01
Earnings per share, diluted USD per share	—	—	(0.00)	0.00	0.01	0.01
Weighted average shares, basic thousands of shares	—	53,852	145,867	309,687	303,521	293,070
Weighted average shares, diluted thousands of shares	—	—	145,867	309,687	303,521	293,070

Fiscal years (ETST's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	16	27	36	698	608	797
Accounts receivable	6	—	—	235	129	356
Inventory	22	—	10	316	504	682
Total current assets	44	27	46	1,258	3,111	3,721
Property and equipment, net	2	—	143	135	1,384	1,518
Right-of-use asset	13	0	201	157	172	95
Goodwill	—	—	2,303	2,303	2,303	2,655
Total assets	65	77	2,728	3,881	7,067	8,969
Accounts payable	174	202	91	531	492	682
Accrued liabilities	234	312	115	855	2,322	1,150
Current portion of long-term debt	—	781	636	31	—	—
Total current liabilities	5,091	1,882	1,307	1,487	3,146	1,929
Long-term debt	—	—	291	61	—	—
Lease liability, non-current	—	—	97	85	38	—
Total liabilities	5,091	1,882	1,608	1,632	3,216	1,929
Accumulated deficit	(33,297)	(30,124)	(30,467)	(29,655)	(27,739)	(24,108)
Total stockholders' equity	(5,027)	(1,805)	1,120	2,249	3,851	7,010
Total liabilities and equity	65	77	2,728	3,881	7,067	8,969
Common shares outstanding (cover page) thousands of shares	53,183	54,183	282,611	309,982	294,298	288,174

Fiscal years (ETST's year ends in late March)

In thousands of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	(4,383)	3,173	(365)	812	3,254	3,631
Stock-based compensation	—	—	5	0	—	—
Depreciation and amortization	2	—	—	150	152	—
Net cash from operating activities	(197)	(168)	(1,013)	1,206	4,372	1,941
Purchases of property and equipment	—	—	—	27	753	757
Net cash from investing activities	—	2	—	(27)	(1,881)	(1,904)
Proceeds from issuing common stock	61	48	564	110	—	—
Share repurchases	—	—	—	178	1,466	471
Net cash from financing activities	182	173	1,017	(518)	(1,716)	(713)
Net change in cash	(15)	7	3	662	776	(676)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.